Results of extraordinary general meeting in Pharma Equity Group A/S
June 03 2024 - 9:17AM
UK Regulatory
Results of extraordinary general meeting in Pharma Equity Group A/S
|
|
|
|
|
|
|
|
Results of extraordinary general meeting in Pharma Equity
Group A/S |
|
|
3 June 2024
Company announcement no. 19
Pharma Equity Group A/S today held an extraordinary general meeting
with the following results:
- The company's share capital will be reduced by a nominal value
of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00
to a nominal value of DKK 102,296,388.30 by allocation to a
specific reserve pursuant to section 188(1)(3) of the Danish
Companies Act. The capital reduction will be made by a proportional
reduction of the denomination of all the company's shares, meaning
that the denomination of the shares will be reduced from DKK 1.00
to DKK 0.1.
Prior to the completion of the capital reduction, the company's
creditors will be encouraged to give notice on any claims against
the company for a period of four weeks. The request will be
published in the Danish Business Authority's IT-system.
- The chair of the general meeting was, with a right of
substitution, authorised to file the resolution adopted with the
Danish Business Authority and to make any such amendments as the
Danish Business Authority may require to register or approve the
resolution adopted.
For further information, please contact:
|
|
|
Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114
Christian Vinding Thomsen, Chairman of the Board of Directors of
Pharma Equity Group A/S, phone: +45 2622 7222 |
|
|
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen
stock exchange, is fully dedicated to advancing the medical
projects of its subsidiary, Reponex Pharmaceuticals A/S. With an
unwavering focus on healthcare, Pharma Equity Group's primary
objective is to bring significant value to Reponex Pharmaceuticals'
medical projects.
The company is committed to providing extensive support,
resources, and expertise to drive the development and success of
these projects. As a strategic partner, Pharma Equity Group works
closely with Reponex Pharmaceuticals, prioritizing the advancement
of innovative medical solutions and breakthrough therapies. Every
effort is currently directed towards ensuring the utmost success
and impact of Reponex Pharmaceuticals' medical projects, with an
unwavering dedication to improving global healthcare outcomes. Only
when the full potential of Reponex Pharmaceuticals has been
unfolded is the intention to explore opportunities to invest in
other companies. This approach ensures a strong commitment to the
current medical projects and their development, while – on the
longer term – remaining open to new strategic investments for
continuous growth.
|
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Oct 2024 to Nov 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Nov 2023 to Nov 2024
